AMEX:PTN

Stock Analysis Report

Executive Summary

Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific product candidates for the treatment of various diseases in the United States.

Snowflake

Fundamentals

Good value with proven track record.

Risks

  • Palatin Technologies has significant price volatility in the past 3 months.
  • Palatin Technologies is covered by less than 3 analysts.

Share Price & News

How has Palatin Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

8.3%

AMEX:PTN

1.1%

US Biotechs

1.1%

US Market


1 Year Return

1.9%

AMEX:PTN

-9.7%

US Biotechs

2.1%

US Market

PTN outperformed the Biotechs industry which returned -10.3% over the past year.

PTN matched the United States of America Market (2%) over the past year.


Share holder returns

PTNIndustryMarket
7 Day8.3%1.1%1.1%
30 Day14.9%-0.6%3.7%
90 Day-18.3%-0.5%2.3%
1 Year1.9%1.9%-8.9%-9.7%4.4%2.1%
3 Year92.2%92.2%7.5%3.8%47.0%37.4%
5 Year20.3%20.3%4.6%-0.4%61.6%43.8%

Price Volatility Vs. Market

How volatile is Palatin Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Palatin Technologies undervalued based on future cash flows and its price relative to the stock market?

6.21x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Palatin Technologies to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Palatin Technologies to establish if it is available at substantial discount.


Price Based on Earnings

Palatin Technologies is good value based on earnings compared to the US Biotechs industry average.

Palatin Technologies is good value based on earnings compared to the United States of America market.


Price Based on Expected Growth

Palatin Technologies is good value based on expected growth next year.


Price Based on Value of Assets

Palatin Technologies is good value based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Palatin Technologies expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

11.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Palatin Technologies's revenue is expected to grow by 9.6% yearly, however this is not considered high growth (20% yearly).

Palatin Technologies's earnings are expected to grow by 11.4% yearly, however this is not considered high growth (20% yearly).

Palatin Technologies's revenue growth is expected to exceed the United States of America market average.

Palatin Technologies's earnings growth is positive but not above the United States of America market average.

Palatin Technologies's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Palatin Technologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Palatin Technologies performed over the past 5 years?

37.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Palatin Technologies has delivered over 20% year on year earnings growth in the past 5 years.

Palatin Technologies's 1-year earnings growth exceeds its 5-year average (44.8% vs 37.1%)

Palatin Technologies's earnings growth has not exceeded the US Biotechs industry average in the past year (44.8% vs 78.4%).


Return on Equity

Palatin Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).


Return on Assets

Palatin Technologies used its assets more efficiently than the US Biotechs industry average last year based on Return on Assets.


Return on Capital Employed

Unable to establish if Palatin Technologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.


Next Steps

Financial Health

How is Palatin Technologies's financial position?


Financial Position Analysis

Palatin Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Palatin Technologies has no long term commitments.


Debt to Equity History and Analysis

Palatin Technologies's level of debt (0.3%) compared to net worth is satisfactory (less than 40%).

Unable to establish if Palatin Technologies's debt level has increased without past 5-year debt data.

Operating cash flow is negative therefore debt is not well covered.

Palatin Technologies earns more interest than it pays, coverage of interest payments is not a concern.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 313.7x debt.


Next Steps

Dividend

What is Palatin Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Palatin Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Palatin Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Palatin Technologies has not reported any payouts.

Unable to verify if Palatin Technologies's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Palatin Technologies has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Palatin Technologies's salary, the management and board of directors tenure and is there insider trading?

11.1yrs

Average board tenure


CEO

Carl Spana (57yo)

19.3yrs

Tenure

US$3,215,939

Compensation

Dr. Carl Spana, Ph.D., is a Co-Founder of Palatin Technologies Inc and has been its Chief Executive Officer and President since June 14, 2000. From June 1996 to June 14, 2000, Dr. Spana served as an Chief  ...


CEO Compensation Analysis

Carl's remuneration is higher than average for companies of similar size in United States of America.

Carl's compensation has been consistent with company performance over the past year, both up more than 20%.


Board Age and Tenure

11.1yrs

Average Tenure

65.5yo

Average Age

The average tenure for the Palatin Technologies board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

More shares have been bought than sold by Palatin Technologies individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$62707 Aug 19
J. Hull
EntityIndividual
Role
Member of the Board of Directors
Director
Shares800
Max PriceUS$0.78
BuyUS$43,25005 Aug 19
Stephen Wills
EntityIndividual
Role
Chief Financial Officer
CFO, COO
Shares50,000
Max PriceUS$0.86
BuyUS$19,41905 Aug 19
Robert deVeer
EntityIndividual
Role
Member of the Board of Directors
Director
Shares22,580
Max PriceUS$0.86
BuyUS$43,11905 Aug 19
Carl Spana
EntityIndividual
Role
Chief Executive Officer
Co-Founder
Shares50,000
Max PriceUS$0.86
BuyUS$8,22321 Nov 18
Arlene Morris
EntityIndividual
Role
Member of the Board of Directors
Director
Shares12,000
Max PriceUS$0.69
BuyUS$15,76619 Nov 18
Carl Spana
EntityIndividual
Role
Chief Executive Officer
Co-Founder
Shares20,000
Max PriceUS$0.79
BuyUS$15,35619 Nov 18
Stephen Wills
EntityIndividual
Role
Chief Financial Officer
CFO, COO
Shares20,000
Max PriceUS$0.77
BuyUS$8,03419 Nov 18
Alan Dunton
EntityIndividual
Role
Member of the Board of Directors
Director
Shares10,332
Max PriceUS$0.80

Ownership Breakdown


Management Team

  • Steve Wills (62yo)

    CFO, COO

    • Tenure: 21.8yrs
    • Compensation: US$2.76m
  • John K. Prendergast (65yo)

    Co-Founder & Non-Executive Chairman

    • Tenure: 19.3yrs
    • Compensation: US$273.05k
  • Carl Spana (57yo)

    Co-Founder

    • Tenure: 19.3yrs
    • Compensation: US$3.22m
  • Burns McClellan

    Vice President of Investor Relations

    • Tenure: 0yrs

Board Members

  • John K. Prendergast (65yo)

    Co-Founder & Non-Executive Chairman

    • Tenure: 19.3yrs
    • Compensation: US$273.05k
  • Carl Spana (57yo)

    Co-Founder

    • Tenure: 19.3yrs
    • Compensation: US$3.22m
  • Arlene Morris (67yo)

    Director

    • Tenure: 4.3yrs
    • Compensation: US$140.28k
  • Robert deVeer (73yo)

    Director

    • Tenure: 20.8yrs
    • Compensation: US$150.28k
  • Alan Dunton (65yo)

    Director

    • Tenure: 8.3yrs
    • Compensation: US$150.28k
  • Tony Manning (57yo)

    Director

    • Tenure: 2yrs
    • Compensation: US$142.68k
  • Raymond Rosen

    Member of Female Sexual Dysfunction Expert Panel

    • Tenure: 0yrs
  • Michael Perelman

    Member of Female Sexual Dysfunction Expert Panel

    • Tenure: 0yrs
  • J. Hull (67yo)

    Director

    • Tenure: 14yrs
    • Compensation: US$142.78k
  • Angela Rossetti (66yo)

    Director

    • Tenure: 6.3yrs
    • Compensation: US$140.28k

Company Information

Palatin Technologies, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Palatin Technologies, Inc.
  • Ticker: PTN
  • Exchange: AMEX
  • Founded: 1986
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$242.932m
  • Shares outstanding: 227.04m
  • Website: https://www.palatin.com

Number of Employees


Location

  • Palatin Technologies, Inc.
  • Cedar Brook Corporate Center
  • 4B Cedar Brook Drive
  • Cranbury
  • New Jersey
  • 8512
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PTNAMEX (NYSE MKT LLC)YesCommon StockUSUSDOct 1993
PTNADB (Deutsche Boerse AG)YesCommon StockDEEUROct 1993
0KF3LSE (London Stock Exchange)YesCommon StockGBUSDOct 1993

Biography

Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific product candidates for the treatment of various diseases in the United States. The company’s lead pr ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 23:39
End of Day Share Price2019/09/16 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.